Previous close | 1.5750 |
Open | 1.5500 |
Bid | 1.4700 x 734600 |
Ask | 1.4800 x 258500 |
Day's range | 1.4600 - 1.5600 |
52-week range | 1.2800 - 5.7000 |
Volume | |
Avg. volume | 326,887 |
Market cap | 184.671M |
Beta (5Y monthly) | 0.73 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3010 |
Earnings date | 29 Apr 2020 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.15 |
The mean of analysts' price targets for Avita Medical Inc. (RCEL) points to a 209.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first quarter ended March 31, 2022. Financial Highlights and Recent Updates: Reported commercial revenue, which excludes BARDA revenue, of $7.4 mil
VALENCIA, Calif. and MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that a discussion on the RECELL System will be held during the Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary dermatology meeting taking place May 11